ACTION

The main aim of the study is to determine if the oral administration of a tincture containing a mixture of cannabinoid and terpenes for 5 weeks provides effective analgesia of chemotherapy Induced peripheral neurOpathic CIPN. This is a double blind, placebo-controlled, cross-over design randomised controlled trial.

ACTION LOGO

Chief Investigator: Professor Marie Fallon

Number and location of participating sites (by region/country): 1 UK site

 

Funder: NIHR EME

Start and End date

Of grant award: 01 October 2024 - 30 April 2027

Of recruitment: TBC

 

Current Status: In set up

Trial website: TBC

 

Sponsor: ACCORD http://www.accord.ed.ac.uk/

Chief Investigator: Prof. Marie Fallon, Edinburgh Cancer Research Centre (IGC), Crewe Road South, Edinburgh EH4 2XR 

Email: action.trial@ed.ac.uk

 

UK GDPR Privacy Statement: Information can be found in our Patient Information Sheets.

You can find out more about how we use your information:

• at www.hra.nhs.uk/patientdataandresearch

• by asking one of the research team

• by sending an email to the action.trial@ed.ac.uk email address, or the Data Protection Officer: dpo@ed.ac.uk

 

ECTU Involvement: Trial Management / Statistics / Database and/or randomisation service provision

(UKCRC)

This article was published on